Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia

Current Pharmaceutical Design

Volumn 19, Issue 41, 2013, Pages 7185-7195

  Silva, A C ^a,b   Gonzalez Mira E ^c   Sousa Lobo, J M ^a   Amaral, M H ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer's; Drug nanocrystals; Lipid nanoparticles; Liposomes; Micelles; Nanoemulsions; Polymeric nanoparticles; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CLOZAPINE; DONEPEZIL; GALANTAMINE; ILOPERIDONE; LIPOSOME; NANOCARRIER; NANOCRYSTAL; NANOPARTICLE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SOLID LIPID NANOPARTICLE; ZIPRASIDONE; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DELIVERY SYSTEM; GEL; HUMAN; MICELLE; NANOEMULSION; NONHUMAN; OINTMENT; POLYMERIZATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SUSPENSION; TABLET; ANIMAL; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEUROPROTECTIVE AGENTS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84890941075     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281941131219123329     Document Type: Article

References (133)

1. Chue P, Prinzo RS, Binder CE. Do formulation switches exacerbate existing medical illness? Results of an open-label transition to orally disintegrating risperidone tablets. Hum Psychopharmacol 2007; 22: 307-14.
2. Gurevich A, Guller V, Berner Y, et al. Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia? The Journal of Nutrition, Health & Aging 2012; 16: 557-561.
3. Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 2007; 67: 1541-66.
4. Mental and Neurological Disorders: Innovative therapies, innovative collaborations, International Federation Pharmaceutical Manufacturers Associations [homepage on the Internet]. [cited 2012 October 24]. Available from http://www.ifpma.org/
5. Naylor MD, Karlawish JH, Arnold SE, et al. Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 2012; 8: 445-452.
6. Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17: 1206-27.
7. Hampel H, Prvulovic D, Teipel S, et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 2011; 95: 718-28.
8. Jain P and Jadhav HR. Therapeutic Advances in the Treatment of Alzheimers Disease: Present and Future. Current Drug Therapy 2011; 6: 175-185.
9. Gadelha A, Noto CS, Jesus J. Pharmacological treatment of schizophrenia. International Review of Psychiatry 2012; 24: 489-98.
10. Querfurth, HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
11. Brambilla D, Droumaguet B., Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine 2011; 7: 521-40.
12. Naylor MD, Karlawish JH, Arnold SE, et al. Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. Alzheimers Dement 2012. 8; 445-52.
13. Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative disorders. Maturitas 2012. 73; 45-51.
14. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; CD005593.
15. Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009; 63: 799-805.
16. Kapil R, Dhawan S, Beg S, et al. Buccoadhesive films for once-a-day administration of rivastigmine: systematic formulation development and pharmacokinetic evaluation. Drug Dev Ind Pharm 2012; 0: 1-15.
17. Stahl SM. Essential Psyhopahramacology: Neuroscientific Basis and Practical Applications. 2nd ed. New York: Cambridge University Press 2005.
18. Meltzer HY. Update on Typical and Atypicl Antipsychotic Drugs. Annual Review of Medicine 2013; DOI: 10.1146/annurev-med-050911-161504.
19. Off-Label Use of Atypical Antipsychotics: An Update, Agency Healthcare Research Quality [homepage on the Internet] [cited 2012 October 24]. Available from http://www.ncbi.nlm.nih.gov/
20. Edwards JG. Risperidone for schizophrenia. BMJ 1994; 308: 1311-2.
21. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253-73.
22. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14: 87-92.
23. Chue P, Welch R, Binder, C. Acceptability and disintegration rates of orally disintegrating risperidone tablets in patients with schizophrenia or schizoaffective disorder. Can J Psychiatry 2004; 49: 701-3.
24. Heemstra LB, Finnin BC, Nicolazzo, JA. The buccal mucosa as an alternative route for the systemic delivery of risperidone. J Pharm Sci 2010; 99: 4584-92.
25. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009; 9: 9-31.
26. Rosenheck, RA, et al. Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia. New Engl J Med 2011; 364: 842-51.
27. Rabinowitz JD, Zaffaroni AC, Inventor; Alexza Pharmaceuticals, assignee. Delivery of antipsychotics through an inhalation route. United States patent US 08173107. 2012 May.
28. Aggarwal G, Dhawan S, Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm 2013; 39: 39-50.
29. Silva AC, Santos D, Ferreira D, et al. Lipid-based Nanocarriers As An Alternative for Oral Delivery of Poorly Water- Soluble Drugs: Peroral and Mucosal Routes. Curr Med Chem 2012; 19: 4495-510.
30. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012; 163: 34-45.
31. Torchilin V. Liposomes in Drug Delivery. In: Siepmann J, Siegel RA, Rathbone MJ, Eds. Fundamentals and Applications of Controlled Release Drug Delivery. Springer US 2012; pp. 289-328.
32. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012; 7: 49-60.
33. Ganta S, Deshpande, D, Korde A, et al. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol 2010; 27: 260-73.
34. Rajpoot P, Pathak K, Bali V. Therapeutic applications of nanoemulsion based drug delivery systems: a review of patents in last two decades. Recent Pat Drug Deliv Formul 2011; 5: 163-72.
35. Muller RH, Shegokar R, Keck, CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol 2011; 8: 207-27.
36. Pardeike J, Hommoss, A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366: 170-84.
37. Patel T, Zhou J, Piepmeier JM, et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 2012; 64: 701-5.
38. Gagliardi M, Bardi G, Bifone A. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the CNS. Ther Deliv 2012; 3: 875-87.
39. Wang GD, et al. Pharmaceutical nanocrystals. Curr Opin Chem Eng 2012; 1: 102-7.
40. Müller RH, Gohla S, Keck CM. State of the art of nanocrystals - Special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 2011; 78: 1-9.
41. Gong J, Chen M, Zheng Y, et al. Polymeric micelles drug delivery system in oncology. J Control Release 2012; 159: 312-23.
42. Gaucher G, Satturwar P, Jones, MC, et al. Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 2010; 76: 147-58.
43. Gao L, Liu G, Ma J, et al. Drug nanocrystals: In vivo performances. J Control Release 2012; 160: 418-30.
44. Lopes CM, Oliveira R, Silva AC. Pharmaceutical Approaches for Optimizing Oral Anti-Inflammatory Delivery Systems. Curr Med Chem Anti Inflamm Anti Allergy Agents 2011; 10: 154-65.
45. Silva AC, Santos D, Ferreira D, et al. Advances in Nanoparticulate Carriers for Oral Delivery of Peptides and Proteins: Polymeric vs. Lipid Nanoparticles. In: Nalwa HS Eds. Encyclopedia of Nanoscience and Nanotechnology. American Scientific Publishers 2011; pp. 133-46.
46. Couvreur P. Nanoparticles in drug delivery: Past, present and future. Adv Drug Deliv Rev 2013; 65(1): 21-3.
47. Cooper ER. Nanoparticles: A personal experience for formulating poorly water soluble drugs. J Control Release 2010; 141: 300-2.
48. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238-52.
49. Gregoriadis G. The carrier potential of liposomes in biology and medicine (second of two parts). N Engl J Med, 1976. 295(14): p. 765-70.
50. Gregoriadis G. The carrier potential of liposomes in biology and medicine (first of two parts). N Engl J Med 1976; 295: 704-10.
51. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev 2012; 64:302-15.
52. Arumugam K, Subramanian G, Mallayasamy S, et al. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 2008; 58: 287.
53. Degim Z, Mutlu NB, Yi{dotless}lmaz Ş, et al. Investigation of liposome formulation effects on rivastigmine transport through human colonic adenocarcinoma cell line (CACO-2). Pharmazie 2010; 65: 32-40.
54. Mutlu, NB, Degim Z, Yi{dotless}lmaz Ş, et al. New perspective for the treatment of Alzheimer diseases: Liposomal rivastigmine formulations. Drug Dev Ind Pharm 2011; 37: 775-89.
55. Li W, Zhou Y, Zhao N, et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Phar 2012; 34: 272-9.
56. Phachonpai W, Wattanathorn J, Muchimapura S, et al. Neuroprotective Effect of Quercetin Encapsulated Liposomes: A Novel Therapeutic Strategy against Alzheimer's Disease. Am J Appl Sci 2010; 7: 480-5.
57. Salama HA, Mahmoud AA, Kamel AO, et al. Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route. Colloids Surf B 2012; 100: 146-54.
58. Salama HA, Mahmoud AA, Kamel AO, et al. Brain delivery of olanzapine by intranasal administration of transfersomal vesicles. J Liposome Res 2012; 22: 336-45.
59. Chen H, Khemtong C, Yang X, et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today 2011; 16: 354-60.
60. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2012; http://dx.doi.org/10.1016/j.ijpharm.2012.08.042.
61. Date AA, Desai N, Dixit, R, et al. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine 2010; 5: 1595-1616.
62. Chakraborty S, Shukla D, Mishra B, et al. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009; 73: 1-15.
63. Kumar M, Pathak K, Misra A. Formulation and Characterization of Nanoemulsion-Based Drug Delivery System of Risperidone. Drug Dev Ind Pharm 2009; 35: 387-95.
64. Kumar M, Misra A, Babbar AK et al. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008; 358: 285-91.
65. Kumar M, Misra A, Pathak K. Formulation and Characterization of Nanoemulsion of Olanzapine for Intranasal Delivery. PDA J Pharm Sci Tech 2009; 63: 501-11.
66. Kumar M, Misra A, Misra AK, et al. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J Drug Target 2008; 16: 806-14.
67. Bahadur S, Pathak K. Buffered Nanoemulsion for Nose to Brain Delivery of Ziprasidone Hydrochloride: Preformulation and Pharmacodynamic Evaluation. Curr Drug Deliv 2012; 9: 596-607.
68. Soliman KA, Ibrahim HK, Ghorab MM. Formulation of Risperidone as Self-Nanoemulsifying Drug Delivery System in Form of Effervescent Tablets. J Disp Sci Tech 2011; 33: 1127-33.
69. Kanuganti S, Jukanti R, Veerareddy, PR, et al. Paliperidone-Loaded Self-Emulsifying Drug Delivery Systems (SEDDS) for Improved Oral Delivery. J Disp Sci Tech 2011; 33: 506-15.
70. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2012; 64:83-101.
71. Lucks JS, Müller RH, Inventor; MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE GmbH, assignee. Medication vehicles made of solid lipid particles (Solid Lipid Nanospheres - SLN), European patent EP 0605497. April 1993.
72. Gasco MR, Inventor; Gasco MR, assignee. Method for producing solid lipid microspheres having a narrow size distribution, European patent EP P0526666. February 1993.
73. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002; 54: 131-55.
74. Silva AC, Kumar A, Wild W, et al. Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int J Pharm 2012; 436: 798-805.
75. Das S, Ng WK, Tan RBH. Are nano structured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): Development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? Eur J Pharm Sci 2012; 47: 139-51.
76. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
77. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011; 8: 2101-41.
78. Bondi ML, Montana G, Craparo, EF, et al. Ferulic Acid-Loaded Lipid Nanostructures as Drug Delivery Systems for Alzheimers Disease: Preparation, Characterization and Cytotoxicity Studies. Curr Nanosci 2009; 5: 26-32.
79. Gobbi M, Re F, Canovi M, et al. Lipid-based nanoparticles with high binding affinity for amyloid-p1-42 peptide. Biomaterials 2010; 31: 6519-29.
80. Amidon GL, Lennernäs H, Shah VP, et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in vitro Drug Product Dissolution and in vivo Bioavailability. Pharm Res 1995; 12: 413-20.
81. Chakraborty S, Shukla D, Misra B, et al., Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009; 73: 1-15.
82. Silva AC, Lopes CM, Santos D, et al. Risperidone Release from Solid Lipid Nanoparticles (SLN): Validated HPLC Method and Modelling Kinetic Profile. Curr Pharm Anal 2012; 8: 307-16.
83. Silva AC, González-Mira E, García ML, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound. Colloid Surface B 2011; 86: 158-65.
84. Silva AC, Amaral MH, González-Mira E, et al. Solid lipid nanoparticles (SLN) - based hydrogels as potential carriers for oral transmucosal delivery of Risperidone: Preparation and characterization studies. Colloid Surface B 2012; 93: 241-48.
85. Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011; 19: 468-74.
86. Kumar S, Randhawa JK. Preparation and characterization of Paliperidone loaded solid lipid nanoparticles. Colloid Surface B 2013; 102: 562-68.
87. Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia Am J Health Pharm 2008. 65: 403-13.
88. Vivek K, Reddy H, Murthy RS. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech 2007; 8: E83.
89. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004; 95: 627-38.
90. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005; 107: 215-28.
91. Tosi G, Constantino L, Ruozi B, et al. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008; 5: 155-74.
92. Nahar M, Dutta T, Murugesan S, et al. Functional polymeric nanoparticles: an efficient and promising tool for active delivery of bioactives. Crit. Rev. Ther Drug Carrier Syst 2006; 23: 259-318.
93. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007; 32: 1054-82.
94. Dikpati A, Madgulkar AR, Kshirsagar SJ, et al. Targeted Drug Delivery to CNS using Nanoparticles. J Adv Pharm Sci 2012; 2: 179-91.
95. Patel T, Zhou J, Piepmeier JM, et al. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 2012; 64: 701-5.
96. Vijaya RC, Tamilselvan N, Balakumar K, et al. Blood brain barrier: surface modified nanocarriers and in vitro models to treat Alzheimer's disease - A review. Internat J Adv Pharm Res 2012; 3: 798-804.
97. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharm Sci 1994; 15: 215-20.
98. Craparo, EF, Pitarresi J, Bondi ML, et al. A Nanoparticulate Drug-Delivery System for Rivastigmine: Physico-Chemical and in vitro Biological Characterization. Macromol Bio 2008; 8: 247-59.
99. Panyam J, Dali MM, Sahoo SK, et al. Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. J Control Release 2003; 92: 173-87.
100. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug 2004; 21: 387-422.
101. Lescure F, Zimmer C, Roy D, et al. Optimization of polyalkylcyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics. J Colloid Interf Sci 1992; 154: 77-86.
102. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies. European J Pharm Biopharm 2010; 76: 189-99.
103. Chandy T, Sharma CP. Chitosan-as a Biomaterial. Artif Cell Blood Sub 1990; 18: 1-24.
104. Kaur S, Rao R, Hussain A, et al. Preparation and Characterization of Rivastigmine Loaded Chitosan Nanoparticles. J Pharm Sci Res 2011; 3: 1227-32.
105. Fazil M, Shadab MD, Haque S, et al, Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012; 47: 6-15.
106. Barnabas W, Malay SK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomedicine 2010; 6: 144-52.
107. Barnabas W, Malay SK, Santhi K, et al. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008; 70: 75-84.
108. Iannone M, Cosco D, Cilurzo F, et al. A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB. Neurosci Lett 2010; 469: 93-6.
109. Mathew A, Aravind A, Brahatheeswaran D, et al. Amyloid-Binding Aptamer Conjugated Curcumin-PLGA Nanoparticle for Potential Use in Alzheimer's Disease. BioNanoScience 2012; 2: 83-93.
110. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomat 2011; 7: 4169-76.
111. Jug M, Kos I, Becirevic-Lacan M. The pH-dependent complexation between risperidone and hydroxypropyl-P-cyclodextrin. J Incl Phenom Macro 2009; 64: 163-71.
112. Jug M, Becirevic-Lacan M. Screening of Mucoadhesive Microparticles Containing Hydroxypropyl- Beta-Cyclodextrin for the Nasal Delivery of Risperidone. Comb Chem High T Scr 2007; 10: 358-67.
113. Muthu MS, Rawat MK, Mishra A, et al. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomed-Nanotechnol 2009; 5: 323-33.
114. Singh S, Muthu MS. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine-UK 2007; 2: 233-40.
115. Lin X, Yang S, Gou J, et al. A novel risperidone-loaded SAIB- PLGA mixture matrix depot with a reduced burst release: effects of solvents and PLGA on drug release behaviors in vitro/in vivo. J Mater Sci-Mater M 2012; 23: 443-55.
116. Muthu MS, Singh S. Poly (D, L-Lactide) Nanosuspensions of Risperidone for Parenteral Delivery: Formulation and In-Vitro Evaluation. Curr Drug Deliv 2009. 6: 62-68.
117. Muthu MS, Singh S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine-UK 2008; 3: 305-19.
118. Hu Z, Liu Y, Yuan W, et al. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres. Colloid Surface B 2011; 86: 206-11.
119. Su ZX, Shi YN, Teng LS, et al. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation. Pharm Dev Technol 2011; 16: 377-84.
120. Su Z, Sun F, Shi Y, et al. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere. Chem Pharm Bull 2009; 57: 1251-6.
121. Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs--a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 2004; 113: 151-70.
122. Möschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm 2012; http://dx.doi.org/10.1016/j.ijpharm.2012.09.034.
123. Xu Y, Liu X, Lian R, et al. Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. Int J Pharm 2012; 438: 287-95.
124. Gao L, Liu G, Ma J, et al. Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs. Pharm Res 2012; 1-18.
125. Thombre AG, Shah JC, Sagawa K, et al. In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. Int J Pharm 2012; 428: 8-17.
126. Thombre AG, Caldwell WB, Friesen DT, et al. Solid Nanocrystalline Dispersions of Ziprasidone with Enhanced Bioavailability in the Fasted State. Mol Pharm 2012; 9: 3526-34.
127. Thombre A, Herbig S, Alderman J. Improved Ziprasidone Formulations with Enhanced Bioavailability in the Fasted State and a Reduced Food Effect. Pharm Res 2011; 28: 3159-70.
128. Torchilin V. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm Res 2007; 24: 1-16.
129. Scialabba C, Rocco F, Licciardi M, et al. Amphiphilic polyaspartamide copolymer-based micelles for rivastigmine delivery to neuronal cells. Drug Deliv 2012; 19: 307-16.
130. Ould-Ouali L, Noppe M, Langlois X, et al. Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone. J Control Release 2005; 102: 657-68.
131. Ould-Ouali L, Arien A, Rosenblatt J, et al. Biodegradable self-assembling PEG-copolymer as vehicle for poorly water-soluble drugs. Pharm Res 2004; 21: 1581-90.
132. Rouxhet L, Dinguizli M, Latere, JP, et al., Monoglyceride-based self-assembling copolymers as carriers for poorly water-soluble drugs. Int J Pharm 2009; 382: 244-53.
133. Mathot F, van Beijsterveldt L, Preat V, et al. Intestinal uptake and biodistribution of novel polymeric micelles after oral administration. J Control Release 2006; 111: 47-55.